GSK (NYSE:GSK) Rating Lowered to "Buy" at StockNews.com

GSK (NYSE:GSK - Get Free Report) was downgraded by StockNews.com from a "strong-buy" rating to a "buy" rating in a research note issued to investors on Sunday.

GSK has been the topic of a number of other research reports. Deutsche Bank Aktiengesellschaft cut GSK from a "buy" rating to a "hold" rating in a research note on Friday, November 15th. Guggenheim cut shares of GSK from a "buy" rating to a "neutral" rating in a research note on Thursday, October 31st. Finally, Jefferies Financial Group downgraded shares of GSK from a "buy" rating to a "hold" rating and decreased their price objective for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Seven equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $43.25.

GSK Stock Down 1.4 %

NYSE:GSK traded down $0.48 on Friday, hitting $33.47. 2,901,914 shares of the company's stock were exchanged, compared to its average volume of 5,262,752. The firm has a 50-day moving average price of $34.75 and a 200-day moving average price of $38.41. GSK has a 52 week low of $32.83 and a 52 week high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The company has a market cap of $69.37 billion, a P/E ratio of 21.73, a price-to-earnings-growth ratio of 1.52 and a beta of 0.63.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC boosted its position in shares of GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock valued at $1,185,885,000 after acquiring an additional 2,224,345 shares during the period. Fisher Asset Management LLC grew its position in shares of GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock worth $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Primecap Management Co. CA increased its holdings in shares of GSK by 2.4% during the third quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company's stock worth $607,222,000 after purchasing an additional 342,365 shares during the period. Provident Trust Co. raised its position in shares of GSK by 1.7% in the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company's stock valued at $161,623,000 after buying an additional 66,765 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC boosted its stake in shares of GSK by 30.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company's stock valued at $144,803,000 after buying an additional 833,080 shares during the period. Institutional investors and hedge funds own 15.74% of the company's stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.